**Draft Guidance on Ivacaftor, Tezacaftor**

*(From the Ivacaftor; Ivacaftor, Tezacaftor Co-Packaged Tablets)*

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Ivacaftor, Tezacaftor

**Dosage Form; Route:** Tablet; Oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 150 mg, 100 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females  
   **Additional Comments:** None

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 150 mg, 100 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females  
   **Additional Comments:** None

**Analytes to measure (in appropriate biological fluid):** Ivacaftor and tezacaftor in plasma

**Bioequivalence based on (90% CI):** Ivacaftor and tezacaftor

**Waiver request of in-vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

*For the bioequivalence recommendation of the single entity Ivacaftor Tablet in the Ivacaftor N/A; Ivacaftor, Tezacaftor co-packaged Product, refer to the Product Specific Guidance on Ivacaftor Tablets recommended on March 2015.*

Recommended Feb 2019